Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Lipocine Inc. Director's Dealing 2017

Dec 7, 2017

35074_dirs_2017-12-06_29ade1c7-9d25-4ff4-b77f-995ac01bd6c7.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lipocine Inc. (LPCN)
CIK: 0001535955
Period of Report: 2017-12-06

Reporting Person: BROWN MORGAN R (EVP and CFO)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-12-06 Stock Option (Right to Buy) $3.52 A 75000 Acquired 2027-12-06 Common Stock (75000) Direct

Footnotes

F1: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 6, 2018, while the remaining 2/3 of the shares subject to the award have vesting monthly on a prorata basis over the following two years.